CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Trisol is developing a transcatheter valve replacement system to treat tricuspid regurgitation, a heart valve disease. This innovative device allows for a quicker and safer implantation procedure, aiming to improve patient outcomes and reduce recovery times compared to traditional surgeries.
In Europe, an estimated 6.5M people are affected by heart valve disease (HVD) each year.
Tricuspid regurgitation (TR) is a HVD which occurs when the tricuspid valve fails to close properly, causing blood to flow backward into the right atrium.
Many cases of TR are accompanied by Right Ventricle (RV) Dysfunction.
The gold standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement.
However, high-risk interventions require long recovery time lo…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
